Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
---|---|
Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
ClinicalTrials.gov Identifier: | NCT00622765 |
This study investigates the effectiveness and safety of 12 weeks of treatment with R256918, in overweight and obese patients. The primary measure of effectiveness is the change in body weight at a clinically relevant dosage level during treatment. Additional measures include body mass index (BMI), dual X-ray absorptiometry (DEXA), fasting glucose,lipid levels, and blood pressure. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.
Condition | Intervention | Phase |
---|---|---|
Nutritional and Metabolic Diseases Metabolic Diseases Body Weight Nutrition Disorders Overweight Obesity |
Drug: R256918 Drug: placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Dose Ranging Study to Investigate the Safety and Efficacy of R256918 in Overweight and Obese Subjects |
Estimated Enrollment: | 320 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | June 2008 |
Arms | Assigned Interventions |
---|---|
001: Experimental |
Drug: R256918
5 mg bid
|
002: Experimental |
Drug: R256918
10 mg bid
|
003: Experimental |
Drug: R256918
15 mg bid
|
004: Placebo Comparator |
Drug: placebo
bid
|
This is a randomized (assigned study drug by chance), double-blind (both the patient and investigator do not know whether patient is assigned to receive study drug or placebo), placebo-controlled study involving overweight and obese patients. Patients are randomized to one of 4 treatment groups and receive study drug or placebo for a period of 12 weeks. The study consists of 3 phases: a pretreatment phase (including a screening period of 1 week and a run-in period of 4 weeks), the treatment period of 12 weeks, and a posttreatment phase (consisting of a follow-up visit). Standardized nonpharmacologic therapy (individualized calorie deficit diets containing no more than 30% calories from fat and nutritional counseling) will be administered from Week -4 through the follow-up period. During the treatment period, patients visit the center every two weeks. On each visit, patients come to the clinic after 8 hours fasting. For effectiveness assessments, patients will be weighed and BMI calculated at each visit; waist and hip circumference and DEXA measurements (for body composition and fat mass analysis) will be performed at selected time points. Additional effectiveness assessments from a blood sample include levels of fasting hemoglobin type A1c (HbA1c), glucose, cholesterol, triglycerides, insulin, C-peptide, and gastrointestinal hormones. Insulin sensitivity and beta cell function are evaluated. Safety evaluations, including incidence of adverse events, clinical laboratory results, vital signs, and electrocardiograms, are performed during the study. Patients complete a questionnaire related to stomach/bowel symptoms (GI) throughout the study. Blood samples will also be drawn for pharmacogenomic analysis and pharmacokinetic analyses. The overall duration of the study for each patient is approximately 19 weeks. The study hypothesis is that treatment with R256918 will cause a change in body weight compared to placebo and will be well tolerated in overweight and obese patients. This hypothesis will be investigated at each dosage level to determine a clinically relevant dose.
5 mg capsules, 10 mg capsules, 15 mg capsules, or matching placebo capsules taken orally.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Responsible Party: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C ( Kirk Ways ) |
Study ID Numbers: | CR011362 |
Study First Received: | December 21, 2007 |
Last Updated: | November 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00622765 |
Health Authority: | United States: Institutional Review Board |
Obesity, Overweight, Body Weight, Body Size, Nutritional
and Metabolic Diseases |
Body Weight Signs and Symptoms Obesity Metabolic Diseases |
Nutrition Disorders Overnutrition Overweight Metabolic disorder |